QualityDipStocks / Health Care · Pharmaceuticals
Bausch Health Companies BHC
Outside our quality screen, so we don’t track its dips. It’s 10% below its 52-week high.
Outside our quality screen. No fair value estimate for now: the model’s result is too extreme to stand behind.
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- −10%
- Risk vs market
- Market-likebeta 1.04
5 bullish · 5 bearish See why
Repriced or dip?
Near its high
The price is 10% below its 52-week high (Oct 29), but the business held up: net cash (cash minus debt) 0.0% of market cap since the high, shares outstanding unchanged, operating margin 0.0 pts.
Some numbers held up (net cash (cash minus debt) 0.0% of market cap since the high, shares outstanding unchanged, operating margin 0.0 pts), others slipped. The price is 10% below its 52-week high.
The price is 10% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
Estimate unreliable for BHC: the model gives 1190% above the price, more than we can stand behind (usually peak-cycle cash flow, heavy debt, or cash flows that include customer or loan balances). We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much BHC moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 4.9× the S&P 500’s.
- Beta vs S&P 500
- 1.04
- Volatility
- 63% vs 13% SPY
- Correlation SPY
- 0.21
- Correlation QQQ
- 0.13
How it ranks
Where BHC stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 3 measures
- Revenue growth, last 12 months+11% · vs the 12 months beforeTop 45%of 1,814
- Operating margin11% · of sales kept as operating profitLowest 47%of 1,288
- Return on invested capital5.9% · profit per dollar of capitalLowest 29%of 838
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
FCF value $109.61
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationFree-cash-flow yield of 61.1% (price / FCF 1.6×): $1.9B of free cash in the last 12 months.
Cash returnsFree cash flow grew 70% over the last 12 months vs the 12 months before.
ProfitabilityOperating margin widened to 17.7% in FY2025 from 11.0% in FY2023 (SEC filings).
GrowthSales grew 11% to $11.1B over the last 12 months vs the 12 months before (SEC filings).
ValuationEV/EBITDA of 8.8×: modest for what the business earns before interest, tax and depreciation.
Top bearish points 5 of 5
Balance sheetOperating income covers interest only 0.8× over the last 12 months.
ProfitabilityLost $841M over the last 12 months (net income, SEC filings).
Balance sheetNet debt of $18.2B, 595% of the market cap (Sep 30, 2026).
ProfitabilityReturn on invested capital of 6%, below the 9.5% discount rate our DCF uses.
QualityDoesn’t pass our quality screen: net debt 4.4× EBITDA (limit 3×).
All fundamentals
FCF yield 61.1% · Sales +11%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- 1.6×
- FCF yield
- 61.1%
- EV / EBITDA
- 8.8×
- Price / sales
- 0.27×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $3.1Bprice × diluted shares
- Enterprise value
- $21.2B
Growth
- Revenue, 12 months
- $11.1B
- Sales growth, 12 months
- +10.8%vs the 12 months before
- Sales growth, 3 yrs
- +8.1%/yrfrom FY2022
- Diluted EPS, 12 months
- −$2.25
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$841M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 11.2%
- Net margin
- −7.6%
- FCF margin
- 16.8%
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- 6%
Balance sheet
- Cash & short-term inv.
- $2.5B
- Total debt
- $20.6B
- Net cash
- −$18.2B
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- 0.8×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $1.9B
- FCF growth, 12 months
- +70%
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +1.4%diluted shares vs a year ago
- Stock-based comp
- $242M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Bausch Health Companies’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $1.6B · Sales +10%
- Free cash flow, 12 months$1.6B
- Free-cash-flow yield61.1%
- Free-cash-flow margin15%
- Gross margin73%
- Operating margin34%
- Return on invested capital18%
- Return on equity−11040%
- Sales growth (latest quarter vs year-ago quarter)+10%
- Net debt / EBITDA4.4×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $8.02
- 52-wk lowlowest close, 1 year$4.43−44.8%
- PriceMon Nov 2 close$8.02you are here
- 52-wk highhighest close, 1 year$8.91+11.1%
Momentum & 52-week range
RSI 69 · 5 days +26.3%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
BHC is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Bausch Health Companies in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.